Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

Melanocortin System and Bremelanotide

PT-141 (Vyleesi), central arousal via MC4R, distinct from peripheral PDE5

Evidence grade 3 of 5, Mixed. Read how the Atlas grades evidence.

The written rationale for this grade is still being prepared.

FDA
Bremelanotide (Vyleesi) FDA-approved 2019 for premenopausal women with HSDD; NOT approved for male ED

Reference only. Not medical advice.

What can go wrong

The most common adverse effects are nausea (frequent enough to be dose-limiting in some), flushing, headache, and injection-site reactions; bremelanotide transiently raises blood pressure and lowers heart rate, so it is contraindicated in uncontrolled hypertension or cardiovascular disease and limited to no more than one dose per 24 hours and eight per month. Repeated use can cause focal skin hyperpigmentation. The related research peptide melanotan II, sold on the gray market, is unregulated, may be contaminated, and has been linked to changing moles and other harms, it should not be used.

This is something to take to a clinician. The Atlas can tell you what is known about melanocortin system and bremelanotide in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.

Bremelanotide (PT-141) is a synthetic melanocortin receptor agonist acting primarily at MC4R in the central nervous system to promote sexual arousal, a fundamentally different mechanism from PDE5 inhibitors, which act peripherally on penile vasculature. It derives from the earlier compound melanotan II. The FDA approved it in 2019 as Vyleesi, a subcutaneous injection, for hypoactive sexual desire disorder (HSDD) in premenopausal women. It is NOT FDA-approved for male erectile dysfunction; earlier male ED development was halted, partly over blood-pressure increases, though it has continued to draw research and off-label interest.

A drug that acts on the brain's arousal circuitry rather than the penile blood vessels.

What people take it for

These are the reasons people give for taking it. They are not effects it has been shown to have.

  • FDA-approved for premenopausal female HSDD
  • Investigated (not approved) for male ED
  • Central-arousal mechanism of academic interest

How it is supposed to work

Melanocortin peptides act at MC3R/MC4R in hypothalamic and limbic regions implicated in sexual motivation. Bremelanotide's agonism, thought to involve MC4R-bearing circuits, increases central sexual arousal and, in men, can produce erections independent of direct genital stimulation, distinguishing it from PDE5 inhibitors, which require nitric-oxide-driven local arousal to work. The exact downstream circuitry (likely overlapping with dopaminergic and oxytocinergic pathways) is not fully resolved.

Central vs peripheral, and why male development stalled

PT-141 promised to treat the desire/arousal side that PDE5 inhibitors cannot touch. But MC4R activation also raises blood pressure and heart rate, and during male ED trials transient hypertension raised safety concerns for a population already enriched for cardiovascular disease. Development pivoted to female HSDD, where it cleared approval in 2019 despite modest effect sizes (small but statistically significant improvements in desire and distress). Its parent compound melanotan II is sold illicitly online as a tanning/erection 'peptide' with no quality control, a genuine safety hazard.

Safety in detail

Bremelanotide raises blood pressure and is contraindicated in cardiovascular disease and uncontrolled hypertension; it requires physician evaluation. Unregulated melanotan II peptides should not be used.

What people get wrong

  • Often saidBremelanotide is an approved male ED drug

    ActuallyIt is FDA-approved only for premenopausal women with HSDD. Use in men for ED is off-label/investigational and was constrained by cardiovascular concerns.

  • Often saidMelanotan II peptides from online vendors are a safe libido/tanning hack

    ActuallyMelanotan II is unapproved, unregulated, and linked to nausea, blood-pressure changes, and concerning changes in moles. It is not a sanctioned therapy and carries real risk.

Who profits, and who pushes back

Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.

How we got here

Bremelanotide originated from melanocortin research at the University of Arizona, where melanotan peptides were studied for tanning. Palatin Technologies developed PT-141 first as an intranasal then subcutaneous agent, pursuing male ED before pivoting to female sexual dysfunction after cardiovascular signals. AMAG Pharmaceuticals commercialized Vyleesi following 2019 FDA approval. Brands and telehealth vendors have since marketed compounded 'PT-141' off-label; Ēnel notes such compounded use is outside the approved indication.

  1. 1990sMelanotan peptides studied for tanning at University of Arizona
  2. 2004-2008PT-141 trialed intranasally/subcutaneously for male ED; halted over BP
  3. 2019FDA approves Vyleesi (bremelanotide) for premenopausal female HSDD
  4. 2020sOff-label and compounded 'PT-141' marketed by telehealth and gray-market vendors

At a glance

Target
Melanocortin receptors, primarily MC4R (CNS)
FDA approval
2019, Vyleesi, female HSDD only
Route
Subcutaneous autoinjector
Mechanism class
Central arousal, not peripheral vasodilation
Notable side effect
Nausea; transient blood-pressure rise; focal hyperpigmentation with repeated use

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about Melanocortin System and Bremelanotide. A short entry is not a safe entry.

  • Cost and market. We have not documented what it sells for or who sells it.
  • Supply chain. We have not mapped where it is made.
  • Who uses it. We have not documented the user groups.
  • What could change. No forward-looking summary yet.
  • How it compares. We have not set it against the alternatives.
  • Children and teenagers. We have not checked what is known about younger people.

Sources

The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.

The studies that matter

  • Diamond et al., intranasal PT-141 for ED2004-2006

    Early trials showed centrally-mediated erectile responses to bremelanotide in men, establishing the melanocortin mechanism but flagging blood-pressure effects

  • RECONNECT trials (Vyleesi, female HSDD)2019

    Two phase 3 RCTs supported FDA approval for premenopausal HSDD, showing small but significant improvements in desire and reductions in distress vs placebo

  • Molinoff et al., PT-141 pharmacology review2003

    Characterized bremelanotide as a melanocortin agonist producing arousal through central, not vascular, mechanisms